Want to see GLMD full AI Analyst Report?
GLMD Stock Chart & Stats
$0.51
$0.01(2.75%)
At close: 4:00 PM EDT
$0.51
$0.01(2.75%)
Day’s Range― - ―
52-Week Range$3.29 - $13.20
Previous Close$0.53
Volume60.58K
Average Volume (3M)84.25K
Market Cap
$37.34M
Enterprise Value-$11.64
Total Cash (Recent Filing)$15.45M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.15
Next Earnings
May 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.00
Shares Outstanding1,041,565
10 Day Avg. Volume86,643
30 Day Avg. Volume84,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-12.48
Revenue Forecast (FY)$5.72M
Bulls Say, Bears Say
Bulls Say
Minimal LeverageNear-zero debt limits interest obligations and reduces balance-sheet risk while Galmed funds development. This provides greater financial flexibility than a highly leveraged biotech, although the benefit is constrained by ongoing cash burn.
Diversified Colospan PlatformColospan’s successful feasibility study supports development of a second colorectal-surgery platform beyond CG-100. A broader device portfolio could diversify future commercialization opportunities and reduce dependence on a single product.
Aramchol Pipeline ExpansionThe preclinical combination result broadens Aramchol’s potential beyond liver disease into oncology and may support future development or partnering. However, translation into clinical benefit remains unproven and requires additional studies.
Bears Say
No Revenue And Persistent LossesZero revenue leaves Galmed without an operating base to fund research, administration, or commercialization. Persistent losses, including renewed deterioration in 2025 and TTM, make the path to self-sustaining profitability dependent on successful pipeline execution.
Ongoing Cash Burn And Shrinking EquityContinued cash consumption and declining equity reduce financial resilience and imply further external funding may be needed if products do not generate revenue. Financing dependence can constrain strategic choices and dilute existing shareholders.
Colospan Funding And Going-Concern RiskThe acquisition adds a financially stressed business requiring substantial investment, increasing execution and integration risk. Galmed must fund European expansion and stabilize Colospan while its own operations remain loss-making, intensifying capital demands.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $3.29 and its highest was $13.20 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $37.34M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 19, 2027 which is in 272 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 1,041,565 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
GLMD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
AIM ImmunoTech
―
Jaguar Animal Health
―
Quoin Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
― Other Institutional Investors
99.94% Public Companies and
Individual Investors